Drug profile · INN
sulfasalazine
PYRALIN EN
sulfasalazine (PYRALIN EN) is a arachidonate 5-lipoxygenase inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — sulfasalazine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 6
- Data quality
- 0.84
Quick answer
sulfasalazine (PYRALIN EN) is a arachidonate 5-lipoxygenase inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Arachidonate 5-lipoxygenase inhibitor
Primary target: Polyunsaturated fatty acid 5-lipoxygenase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sulfasalazine?
sulfasalazine (PYRALIN EN) is a arachidonate 5-lipoxygenase inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sulfasalazine?
PYRALIN EN is a marketed brand name for sulfasalazine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sulfasalazine?
sulfasalazine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.